41 results about "Weight Loss Program" patented technology

A remotely or locally actuable refrigerator door lock has a body portion that is attached to the cabinet and a door portion that is attached to an edge of the door. A latch in the body portion engages a strike plate in the door portion and can be lifted out of engagement to open the refrigerator. The door lock assembly may be connected to a touch-screen device or via a USB or ethernet connection to a remote host computer. The host computer keeps an audit trail of the times and personnel accessing each refrigerator, and a temperature audit trail. The system may be used in hospital for controlling access to pharmaceuticals or may be used in a weight loss program. Temperature and humidity sensors are positioned within the refrigerator cabinet. The door lock may have battery power for portable or mobile applications.

A remotely actuable refrigerator door lock has a body portion attached to the cabinet and a door portion attached to an edge of the door. A latch in the body portion engages a strike plate in the door portion and can be remotely lifted to open the refrigerator. The door lock assembly is connected to a remote host computer via a USB or ethernet connection. Temperature and/or humidity in the refrigerator is compared with a predetermined limit, and in the event the sensed value is beyond the limit, the remote opening functionality is disabled, and a microprocessor automatically generates and sends a warning message. A key lock can provide access in the event of an adverse temperature or humidity event. The host computer keeps an audit trail of the times and personnel accessing each refrigerator. The system may be used in hospital for controlling access to pharmaceuticals or may be used in a weight loss program.

Disclosed herein are methods and systems for influencing behavior in social settings. The method/system gathers information about the behavior of socially connected entities/individuals, for example, and computes monetary rewards, for example, to distribute to these individuals, thus giving them incentive to adopt a particular behavior. Examples of applications include health insurance, car insurance, power production, weight-loss programs, and public utilities. These methods and systems can be twice as efficient in terms of effect per cost as compared to previous approaches. These methods and systems can improve overall quality of service among computer networks.

A remotely actuable refrigerator door lock has a body portion that is attached to the cabinet and a door portion that is attached to an edge of the door. A latch in the body portion engages a strike plate in the door portion and can be lifted out of engagement to open the refrigerator. The door lock assembly is connected to a remote host computer via a USB or ethernet connection. The host computer keeps an audit trail of the times and personnel accessing each refrigerator. The system may be used in hospital for controlling access to pharmaceuticals or may be used in a weight loss program. A key lock can provide access in the event of a power failure.

A mobile programmable device and method providing aural, visual or mechanical stimulus in a program for facilitating weight loss or maintenance. The device may be a mobile phone programmed with a downloadable mobile application. The application program may be modified as a result of user behavior or responses to the application. Thus the application can provide a personalized aid in weight loss control. The application may also provide a link for the user to live coaching assistance, support text messaging or email.

Disposable test strips and a wet chemistry method for measuring each of beta-hydroxybutyrate alone, combined beta-hydroxybutyrate and acetoacetate or total ketone bodies (i.e., beta-hydroxybutyrate, acetoacetate and acetone) in human bodily fluid samples, including but not limited to urine, saliva or sweat are described. The test strips need only be dipped in the sample and can be used by anyone in almost any milieu. Measurement can be made electrochemically, spectrophotometrically, fluorometrically or by comparision to a color standard. Combined acetoacetate and beta-hydroxybutyrate which account for 97-98% of total ketone bodies and may be measured in a cyclic reaction that occurs at pH about 7.0 to about 8.3 with beta-hydroxybutyrate dehydrogenase, (beta-HBD), nicotinamide adenine dinucleotide, a tetrazolium dye precursor and an electron mediator. Using this reaction, false positive results obtained from urine samples taken from patients on sulfhydryl drugs are avoided. beta-HBD from some sources was found to cause false negative results in samples (e.g. urine) containing high chloride content due to chloride inhibition of beta-HBD. Using a simple test for chloride inhibition, it was found that beta-HBD from Alcaligenes is not so inhibited. Using either beta-HBD that is not inhibited by chloride or using 10-20 times the normal concentration of this enzyme eliminates false negatives in samples having substantial chloride content, such as urine, both in the reaction described above and in other reactions disclosed for measuring each of beta-hydroxybutyrate alone, combined beta-hydroxybutyrate and acetoacetate and total ketone bodies, all of which reactions occur in the pH range of about 8.6 to about 9.5.

Methods for achieving weight loss goals and maintaining weight loss including selecting an appropriate weight loss program and identifying a weight loss goal, followed by participating in the weight loss program until the weight loss goal is achieved; then ending the weight loss program participation; and consuming an ingestible composition at regular intervals beginning from 1 day to about 7 days after ending the weight loss program, the ingestible composition comprising an effective amount of a multivalent cation and an effective amount of an soluble anionic fiber.

This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.

The invention provides a dietary fiber dispersible tablet capable of satisfying the appetite and shortening the detention time of food in intestinal tract, so as to alleviate hunger sense which often occurs when obesity groups carry out weight loss plan. The dietary fiber dispersible tablet comprises the following materials by weight proportions: 1-60% of wheat bran powder, 10-40% of microcrystalline cellulose and konjaku flour. The dietary fiber dispersible tablet adopts the 'water swelling property' of konjaku polysaccharide to cause that a person eats a small amount and can quickly gets a full feeling, thus helping to inhibit excessive calorie intake; and the dietary fiber dispersible tablet combines the 'nonabsorbable property' of wheat bran crude fiber and the microcrystalline cellulose to help gastrointestinal peristalsis, thus causing the secretion of intestinal enzyme to be increased, accelerating the removal of deposits on intestinal wall, causing the deposits to be excreted to the outside of the body as quickly as possible and keeping digestive tract healthy. The dietary fiber dispersible tablet is convenient for taking and eating, can take effect by taking before dinner (full), and can achieve no 'pain' (hunger, diarrhea, weakness caused by great amount of exercises, fatigue and the like) weight loss.

This invention relates to a dietary supplement for use in a weight loss program, which alleviates insulin resistance in the presence of the metabolic syndrome. The dietary supplement includes, in combination, berberine, banaba leaf extract, and inositol. Also provided is a method of treatment in a weight loss program.

The invention discloses a method and a system for determining a weight loss program. The method comprises the steps of: determining a user's fatness and thinness degree according to the user's physical quality information, and calculating calories requiring to be consumed by the user through daily weight loss according to the target fatness and thinness degree of the user in a planning time; matching N physical exercises meeting the user's own conditions and the exercise habits on that day from a fitness database, wherein N is a positive integer; performing training of the N physical exercisesthrough a trained health exercise model to obtain an exercise sequence and exercise time of the N physical exercises so as to allow the users to consume the daily calories. Therefore, the method andthe system for determining a weight loss program take the consideration of the user own conditions and the user's exercise habits on that day so as to train a personalized exercise scheme suitable forthe user and meeting the user's habits, facilitate the user's good health and improve the user's weight loss effect.

A Nutritionally balanced weight loss program based in a grocery store setting that includes cholesterol screening and blood pressure monitoring, PCP involvement, meal plans, grocery shopping assistance, on-line support, counseling and support, and a health advisor.

This invention relates to a composition of a unique combination of three novel dietary supplements for use in a weight loss program. The composition includes a mood enhancer, an insulin sparing agent, and a peripheral energy blocker. Also provided is a method of treatment in a weight loss program.

A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain.

The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin D, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult.

Weight loss methods and systems are described. In one embodiment, behavior modification program data indicating participation in a weight loss behavior modification program is recorded. Drug therapy program data indicating drug fulfillment of a weight loss drug therapy program drug is recorded, in which the drug fulfillment of the weight loss drug therapy program drug occurs after participation in the weight loss behavior modification program. Whether a weight loss surgical program criterion has been met is determined based on analysis of the behavior modification program data and the drug therapy program data. The weight loss surgical program criterion is based on the participation in the weight loss behavior modification program and the drug fulfillment of the weight loss drug therapy program drug. A surgical weight loss program approval is generated based on a determination that the surgical weight loss program criterion has been met. Additional methods and systems are disclosed.

A weight loss program can be implemented at least partially on a Web server or other computing device. Patient data are input into the computing device. The computing device determines a weight-loss program, including a prescription, and provides the weight-loss program and the prescription to a physician for review before they are provided to the patient.

This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information.